Journal of Clinical Trials
Open Access
ISSN: 2167-0870
ISSN: 2167-0870
Department of Hepato-Gastroenterology, Digestive Oncology and Nutritional Support, CHU Hôtel Dieu, N, France
Research Article
DOVIPA, a phase II study evaluating efficacy and safety of DOstarlimab® and oral VItamin D3 with folinic acid, 5FU, Irinotecan plus oxalipaltin (mFOLFIRINOX) in non pretreated metastatic PAncreatic Cancer.
Author(s): Asmahane Benmaziane*, Dahna Coupez, Nassiba Heba, Fanny Foubert, Jean Emmanuel Mitry, Baptiste Porte, Julien Taïeb, Isabelle Trouilloud, Angélique Vienot, Tassadit Ben belkacem and Jaafar Bennouna
Background: Our phase 2 trial evaluating a new combination of mFOLFIRINOX plus dostarlimab and oral vitamin D3 is justified by the high unmet need in metastatic pancreatic cancer. There is a need to find more effective combined anticancer therapy for patients with metastatic pancreatic cancer. There is also a need to incorporate a high level of translational research to better understand the mechanism of action of dostarlimab with oral vitamin D3. Pancreatic adenocarcinoma is known as a specific model for translational research in oncology because of the multiple mechanisms of resistance for chemotherapy and immunotherapy.
Methods: Our hypothesis is that the innovative regimen mFOLFIRINOX+Dostarlimab+oral vitamin D3 will be sufficiently effective to improve antitumor response in patients in with non-pre-treated metastatic pancreatic Cancer. .. View More»
DOI:
10.35248/2167-0870.25.15.603